Skip to main content

Table 9 Hearing loss 3 months post first fitting compared to baseline: descriptive subgroup analysis by baseline hearing at 500 Hz air-conducted audiometry (> 65 dB or ≤ 65 dB)—ITT set

From: Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Hearing loss 3 months post-fitting compared to baseline—ITT set

Subgroup

Treatment

N

Mean

Std. Dev.

Minimum

Median

Maximum

Less or equal to 65 dB

Placebo

9

37.22

21.23

5.00

40.00

75.00

ACEMg

8

24.38

18.41

5.00

17.50

55.00

More than 65 dB

Placebo

15

26.00

10.21

10.00

25.00

45.00

ACEMg

17

26.76

17.67

− 10.00

25.00

50.00